Exclusive Summary

• A classic, mature antihypertensive combination targeting over 1.28 billion hypertensive patients globally, perfectly aligned with the enormous demand for cost-effective basic chronic disease medications in emerging markets.
• The unique low-dose 10mg:6mg fixed-dose combination (FDC) provides mild and stable blood pressure reduction with minimized side effects, making it ideal for the initial treatment of mild-to-moderate hypertension and elderly or sensitive patients.
• Both active ingredients are listed on the WHO Essential Medicines List and universally recommended by global guidelines, facilitating distributors' easy entry into national public procurement tenders and health insurance systems.
• With originator patents long expired, there are zero cross-border IP risks; distributors can fully leverage China's robust, integrated manufacturing capacity to secure highly competitive procurement costs and lucrative distribution margins.